Toll-like receptor (TLR)3 gene variants may correlate with clinical significance of chronic viral infections including HBV. We aimed to investigate the expression of TLR3 in peripheral blood mononuclear cells (PBMCs) and liver cells of chronic hepatitis B (CHB) patients and its response to pegylated interferon or nucleoside analogue therapy.
Methods
We consecutively enrolled 127 CHB patients and 64 hepatitis B surface antigen-negative, anti-HCV-negative healthy individuals as controls. We compared the TLR3 expressions on fresh PBMCs and liver cells from patients and controls, before and during pegylated interferon or nucleoside analogue therapy.
Results
Compared to controls, patients had a lower TLR3 mean fluorescence intensity (MFI) on PBMCs (mean ±sd 14.61 ±13.49 versus 9.70 ±4.61; P<0.001), independent of age, gender and alanine aminotransferase (ALT; -13.466, 95% CI -17.202, -9.730; P<0.001). Patients had limited TLR3 stains on Kupffer cells, whereas controls had diffuse stains on Kupffer and hepatocytes. Hepatic TLR3 messenger RNA was lower in patients than controls (0.47 ±0.30 versus 1-fold). Using pretreatment TLR3 MFI as a referent, among 5 of 12 pegylated-interferon-treated patients with sustained virological response (SVR), TLR3 MFI was restored to a mean of 1.5- to 1.7-folds immediately after treatment. Among seven non-responders or relapsers, TLR3 MFI reduced to a mean of 0.5- to 0.7-fold. Among 10 entecavir-treated patients with on-treatment virological response, TLR3 MFI gradually was restored to a mean of 1.2-folds during 48-week therapy.
Conclusions
CHB patients have reduced TLR3 expression on PBMCs, independent of age, gender and ALT, and on liver cells. Patients with pegylated-interferon-induced SVR have a more significant restoration of TLR3 expression than those under entecavir.
References
1.
KaoJ.H., ChenD.S.Global control of hepatitis B virus infection. Lancet Infect Dis2002; 2: 395–403.
2.
ChenD.S.From hepatitis to hepatoma: lessons from type B viral hepatitis. Science1993; 262: 369–370.
3.
ChisariF.V., FerrariC.Hepatitis B immunopathogenesis. Annu Rev Immunol1995; 13: 29–60.
4.
IsogawaM., RobekM.D., FuruichiY., ChisariF.V.Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol2005; 79: 7269–7272.
5.
VisvanathanK., SkinnerN.A., ThompsonA.J.V.Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology2007; 45: 102–110.
6.
IwasakiA., MedzhitovR.Toll-like receptor control of the adaptive immune responses. Nat Immunol2004; 5: 987–995.
7.
Ranjith-KumarC.T., MillerW., XiongJ.Biochemical and functional analyses of the human Toll-like receptor 3 ectodomain. J Biol Chem2007; 282: 7668–7678.
8.
NahumA., DadiH., BatesA., RoifmanC.M.The L412F variant of Toll-like receptor 3 (TLR3) is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity. J Allergy Clin Immunol2011; 127: 528–531.
9.
HidakaF., MatsuoS., MutaT., TakeshigeK., MizukamiT., NunoiH.A missense mutation of the Toll-like receptor 3 gene in a patient with influenza-associated encephalopathy. Clin Immunol2006; 119: 188–194.
10.
ZhangS.Y., JouanguyE., UgoliniS.TLR3 deficiency in patients with herpes simplex encephalitis. Science2007; 317: 1522–1527.
11.
BousfihaA., PicardC., Boisson-DupuisS.Primary immunodeficiencies of protective immunity to primary infections. Clin Immunol2010; 135: 204–209.
12.
NeteaM.G., van der MeerJ.W.Immunodeficiency and genetic defects of pattern-recognition receptors. N Engl J Med2011; 364: 60–70.
13.
Al-QahtaniA., Al-AhdalM., AbdoA.Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. J Med Virol2012; 84: 1353–1359.
14.
RongY., SongH., YouS.Association of Toll-like receptor 3 polymorphisms with chronic hepatitis B and hepatitis B-related acute-on-chronic liver failure. Inflammation2013; 36: 413–418.
YehS.H., TsaiC.Y., KaoJ.H.Quantification and genotyping of hepatitis B virus in a single reaction by realtime PCR and melting curve analysis. J Hepatol2004; 41: 659–666.
17.
LokA.S.F., McMahonB.J.Chronic hepatitis B. Hepatology2007; 45: 507–539.
18.
ChenZ., ChengY., XuY.Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol2008; 128: 400–408.
19.
XieQ., ShenH.C., JiaN.N.Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect2009; 11: 515–523.
20.
WoltmanA.M., Op den BrouwM.L., BiestaP.J., ShiC.C., JanssenH.L.Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS ONE2011; 6: e15324.
21.
XuY., HuY., ShiB.HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol2009; 46: 2640–2646.
22.
HeibergI.L., WintherT.N., PaludanS.R., HoghB.Pattern recognition receptor responses in children with chronic hepatitis B virus infection. J Clin Virol2012; 54: 229–234.
23.
WuJ., MengZ., JiangM.Hepatitis B virus suppresses Toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology2009; 49: 1132–1140.
24.
YuS., ChenJ., WuM., ChenH., KatoN., YuanZ.Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/ IKKepsilon and DDX3. J Gen Virol2010; 91: 2080–2090.
25.
FosterG.R., AckrillA.M., GoldinR.D., KerrI.M., ThomasH.C., StarkG.R.Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci U S A1991; 88: 2888–2892.
26.
WuJ., LuM., MengZ.Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology2007; 46: 1769–1778.
27.
TangT.J., KwekkeboomJ., LamanJ.D.The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection. J Viral Hepat2003; 10: 159–167.
28.
LiangT.J.Hepatitis B: the virus and disease. Hepatology2009; 49: S13–S21.
29.
HuangY.W., ChayamaK., TsugeM.Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. Antivir Ther2010; 15: 177–184.
30.
LaiY., YiG., ChenA.Viral double-strand RNA-binding proteins can enhance innate immune signaling by Toll-like receptor 3. PLoS ONE2011; 6: e25837.
31.
PorterfieldJ.Z., DhasonM.S., LoebD.D., NassalM., StrayS.J., ZlotnickA.Full-length hepatitis B virus core protein packages viral and heterologous RNA with similarly high levels of cooperativity. J Virol2010; 84: 7174–7184.
32.
WangK., LiuH., HeY.Correlation of TLR1-10 expression in peripheral blood mononuclear cells with chronic hepatitis B and chronic hepatitis B-related liver failure. Hum Immunol2010; 71: 950–956.
33.
LiN., LiQ., QianZ., ZhangY., ChenM., ShiG.Impaired TLR3/IFN-beta signalling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage. Biochem Biophys Res Commun2009; 390: 630–635.
TjwaE.T., van OordG.W., BiestaP.J., BoonstraA., JanssenH.L., WoltmanA.M.Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection. J Virol2012; 86: 4102–4109.
36.
ChewV., TowC., HuangC.Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst2012; 104: 1796–1807.
